Microglial Tipping Point in Alzheimer's
Analysis based on 6 articles · First reported Jun 04, 2026 · Last updated Jun 07, 2026
The discovery of a critical biological transition in Alzheimer s disease and the identification of microglial states as therapeutic targets could significantly impact the pharmaceutical and biotechnology industries. Companies like Muna Therapeutics>>> involved in developing treatments for neurodegenerative diseases may see increased investment and potential for new drug development, particularly those focusing on immunomodulatory strategies and pathways like TREM2>>>.
Researchers from Vietnamese International Bank>>>, KU Leuven>>>, the UK Dementia Research Institute>>>, and Muna Therapeutics>>>, with funding from the Australia — Australian Research Council>>>, have identified a critical biological transition in Alzheimer s disease that determines whether pathology progresses to dementia. The study, published in Nature Medicine, analyzed human brain tissue from older adults and cognitively healthy centenarians, revealing distinct microglial (brain immune cells) responses associated with disease progression and resilience. They found that microglia transition from an inflammatory state to an antigen-presenting state, marking a key tipping point. Resilience mechanisms were also identified, showing that some individuals avoid this later immune state or uncouple it from tau accumulation. These findings, highlighted by co-senior authors Prof. Bart De Strooper>>>, Prof. Mark Fiers>>>, and Niels Plath>>>, suggest new therapeutic avenues focusing on modulating microglial states, such as the TREM2>>> pathway, rather than solely targeting plaque removal.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard